1. Medtech Insight
  2. >>Archive

CircuLite: Partial Support Enables Patient Management

There is a large group of chronic heart failure patients--more than two million of them worldwide-who are resistant to or have failed drugs or devices, but aren't yet eligible for the cardiac assist devices approved for end-stage patients. Back in 2006, when START-UP first spoke with CircuLite, the company was after those patients, with a small pump that, in providing partial circulatory support, would be in an entirely different category than LVADs. Today, on only a bit more than $36 million in funding, CircuLite has developed the Synergy Pocket Micro-pump, a tiny pump designed to provide partial assist to the heart. Synergy has completed its first-in-man study, and is nearing completion of its European clinical trial supporting a CE mark.

Historically, the market for heart failure devices has gone to extremes. At one end of the spectrum, there are drugs, which manage the symptoms of patients in earlier stages of the disease, and at the other end, there are surgically implanted left ventricular assist devices (LVADs) and artificial hearts, to support patients in end-stage heart failure while they wait for a heart transplant. There is a large group of chronic heart failure patients in the middle—more than two million of them worldwide—who are resistant to or have failed drugs or devices, and are therefore bereft of helpful therapeutic options. Back in 2006, when START-UP first spoke with CircuLite Inc., CEO Paul Southworth explained that his company was after those patients, with a small pump that, in providing partial circulatory support, would be in an entirely different category than LVADs. (See CircuLite Inc., START-UP, July 2006 Also see "CircuLite Inc." - Medtech Insight, 1 July, 2006.).

Today, on only a bit more than $36 million in funding, CircuLite has developed the Synergy Pocket Micro-pump, a tiny pump designed to provide partial assist to the heart.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.